Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study is carried out to assess whether dapagliflozin lowers blood glucose, body weight
and blood pressure, when added to patients existing medications and how it compares with
their usual treatment without added dapagliflozin. Safety data will be collected and analysed
to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have
diabetes, cardiovascular disease and hypertension.